Ret Proto-Oncogene antibody (AA 702-848) (CF®740)

Catalog No. ABIN7659589

This Mouse Monoclonal antibody specifically detects Ret Proto-Oncogene in . It exhibits reactivity toward Human.

Quick Overview for Ret Proto-Oncogene antibody (AA 702-848) (CF®740) (ABIN7659589)

Target: Ret Proto-Oncogene (RET)

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This Ret Proto-Oncogene antibody is conjugated to CF®740

Application: Please inquire

Clone: RET-2663

Product Details anti-Ret Proto-Oncogene Antibody (CF®740)

Binding Specificity: AA 702-848

Purpose: RET Proto-oncogene(RET/2663), CF740 conjugate

Characteristics: The Ret proto-oncogene is structurally related to the growing family of tyrosine kinase transmembrane receptors and is involved in GDNF signaling. RET expression is reported in several regions of the central nervous system, in the developing cranial nerve ganglia and a subset of cells within dorsal root ganglia, in motor neurons in the spinal cord and hindbrain, in neuro-retina and the growing tips of the renal collecting ducts in developing kidney. Alterations in RETgene are associated with diseases including papillary thyroid carcinoma, multiple endocrine neoplasia (type 2A and 2B), familial medullary thyroid carcinoma, and a congenital developmental disorder known as Hirschsprung's disease. Primary antibodies are available purified, or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.

Immunogen: Recombinant fragment (around aa 702-848) of human RET protein

Isotype: IgG2b, kappa

Application Details

Application Notes: For coating for ELISA, order Ab without BSA. Higher concentration may be required for direct detection using primary antibody conjugates than for indirect detection with secondary antibody. Optimal dilution and staining procedure for a specific application should be determined by user. Recommended starting concentrations for titration are 1-2 μg/mL for most applications, or 1 μg/million cells/100 μLfor flow cytometry

Comment:

Positive Control: Breast, Prostate or Colon Carcinoma.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.1 mg/mL

Buffer: PBS, 0.1 % rBSA, 0.05 % azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from light

Storage: 4 °C

Storage Comment:

Stable at room temperature or 37°C for 7 days.

Protect from light

Store at 2 to 8°C. Protect fluorescent conjugates from light

Expiry Date: 24 months

Target Details for Ret Proto-Oncogene

Target: Ret Proto-Oncogene (RET)

Alternative Name: RET Proto-oncogene

Background:

Synonyms: Cadherin family member 12 (CDHF12), Cadherin related family member 16 (CDHR16), ELKS, HSCR1, Hydroxyaryl protein kinase, MEN2A, MEN2B, MTC1, Multiple endocrine neoplasia and medullary thyroid carcinoma 1, Oncogene RET, Proto-oncogene c-Ret, Proto-oncogene tyrosine-protein kinase receptor ret, PTC, RET, RET ELE1, RET51, RET9

Gene Symbol: RET

Molecular Weight: 150 kDa (precursor), 170 kDa (Mature)

Gene ID: 5979

UniProt: P07949

Pathways: RTK Signaling, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation